Research graph
References from Safe prolonged prophylactic use and tolerability of Ashwagandha following COVISHIELD™ vaccination over 24 weeks: a multicentre randomized double-blind placebo-controlled trial. Local targets link to admitted publications; unresolved targets remain external evidence.
COVID-19 management: the vaccination drive in India
10.1016/j.hlpt.2022.100636 · 2022 · External reference
Unresolved reference
External reference
Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population
10.1002/jmv.27708 · 2022 · External reference
COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network cohort study of 99 million vaccinated individuals
10.1016/j.vaccine.2024.01.100 · 2024 · External reference
Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
10.1136/bmj.n1931 · 2021 · External reference
Omicron (B11529) variant of concern: molecular profile and epidemiology
2021 · External reference
COVID-19 pandemic: a pragmatic plan for ayurveda intervention
2020 · External reference
The journey with COVID-19: initiatives by Ministry of AYUSH
10.1016/j.jaim.2021.03.009 · 2021 · External reference
Ayurveda rasayana in prophylaxis of COVID-19
2020 · External reference
Public health approach of ayurveda and yoga for COVID-19 prophylaxis
10.1089/acm.2020.0129 · 2020 · External reference
Unresolved reference
2000 · External reference
Withaniasomnifera (L) Dunal-modern perspectives of an ancient Rasayana from Ayurveda
10.1016/j.jep.2020.113157 · 2021 · External reference
Ayurvedicmedicine: core concept, therapeutic principles, and current relevance
10.1016/s0025-7125(03)00073-7 · 2002 · External reference
Ashwagandha (Withaniasomnifera): current research on the health-promoting activities
10.3390/pharmaceutics15041057 · 2023 · External reference
Immunomodulatory effect of Ashwagandha and its impact on COVID-19
10.21603/2308-4057-2025-1-622 · 2025 · External reference
Withanone from Withaniasomnifera attenuates SARS-CoV-2 RBD-ACE2 interactions
10.2147/dddt.s292805 · 2021 · External reference
Withaniasomnifera: opportunity for clinical repurposing in COVID-19
10.3389/fphar.2021.623795 · 2021 · External reference
Ayurveda botanicals in COVID-19 management: an in silico multi-targetapproach
10.1371/journal.pone.0248479 · 2021 · External reference
A standardized root extract of Withaniasomnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice
10.1016/j.lfs.2007.01.029 · 2007 · External reference
Withaferin a associated differential regulation of inflammatory cytokines
10.3389/fimmu.2018.00195 · 2018 · External reference
Immune response modulation to DPT vaccine by aqueous extract of Withaniasomnifera in experimental system
10.1016/j.intimp.2004.03.005 · 2004 · External reference
Mobile app-reported use of traditional medicine for maintenance of health in India during the COVID-19 Pandemic: cross-sectional questionnaire Study
10.2196/25703 · 2021 · External reference
Unresolved reference
External reference
Randomized double blind placebo controlledtrial of Ashwagandha administration in participants vaccinated against COVID-19 on safety, immunogenicity, and protection with COVID-19 vaccine-A study protocol
10.3389/fmed.2022.761655 · 2022 · External reference
World medical association declaration of Helsinki: ethical principles for medical research involving human subjects
10.1001/jama.2013.281053 · 2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
CONSORT Group. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration
10.1016/j.jclinepi.2005.12.020 · 2006 · External reference
Immune response to COVID-19 in India through vaccination and natural infection
10.26502/fjhs.070 · 2022 · External reference
SARS-CoV-2 reinfection after previous infection and vaccine breakthrough infection through the second wave of pandemic in India: an observational study
10.1016/j.ijid.2022.02.037 · 2022 · External reference
Vaccination coverage and breakthrough infections of COVID-19 during the second wave among staff of selected medical institutions in India
10.1371/journal.pgph.0000946 · 2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
10.1016/s0140-6736(20)32466-1 · 2020 · External reference
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
10.1016/s0140-6736(21)00432-3 · 2021 · External reference
Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study
10.1016/j.vaccine.2021.09.055 · 2021 · External reference
Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses
10.1111/cei.13582 · 2021 · External reference
Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 Omicron subvariants, Czechia, December 2021 to August 2023
10.2807/1560-7917.es.2024.29.35.2300690 · 2024 · External reference
Ashwagandha (Withaniasomnifera (L. Dunal) for promoting recovery in long COVID (APRIL Trial): protocol for a randomised placebo- controlled clinical trial
10.1136/bmjopen-2024-094526 · 2025 · External reference
An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withaniasomnifera) extract: a randomized, double-blind, placebo-controlled study
10.1097/md.0000000000017186 · 2019 · External reference
Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection
10.1371/journal.pone.0253977 · 2021 · External reference
